Curtis Gale Oltmans

This profile gathers the share dealings of Curtis Gale Oltmans across 3 companies, led by Array Biopharma Inc, Fulcrum Therapeutics, Inc. and Avenue Therapeutics, Inc. Between 16 December 2018 and 15 December 2025, the trades on record add up to 14 filings.

In open-market terms, that means 1 purchase worth €8,218 on one side and 5 sales worth €1.3M on the other. On balance, insiders were net sellers of €1.3M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 2 share grants and 6 option exercises. In 2025 alone, the filings show no purchases and 1 sale.

On 17 December 2025 came the latest disclosure, an open-market sale for €38k in Fulcrum Therapeutics, Inc. The latest purchase dates back some time: it was published 1,943 days ago, on 29 June 2021. Typically, a trade is published a median of 2 days after it takes place. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.